| Chronic Lymphocytic Leukemia
Bendeka vs Breyanzi
Side-by-side clinical, coverage, and cost comparison for chronic lymphocytic leukemia.Deep comparison between: Bendeka vs Breyanzi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsBreyanzi has a higher rate of injection site reactions vs Bendeka based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Breyanzi but not Bendeka, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bendeka
Breyanzi
At A Glance
IV infusion
Every 3-4 weeks
Alkylating agent
IV infusion
Single infusion
CD19-directed CAR T cell therapy
Indications
- Chronic Lymphocytic Leukemia
- Indolent B-Cell Non-Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma
- High grade B-cell lymphoma
- Mediastinal (Thymic) Large B-Cell Lymphoma
- Lymphoma, Follicular
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Mantle cell lymphoma
- Marginal Zone B-Cell Lymphoma
Dosing
Chronic Lymphocytic Leukemia 100 mg/m2 IV over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.
Indolent B-Cell Non-Hodgkin Lymphoma 120 mg/m2 IV over 10 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles.
Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma (after one line of therapy) 90 to 110 x 10^6 CAR-positive viable T cells as a single IV infusion, administered 2 to 7 days after lymphodepleting chemotherapy (fludarabine 30 mg/m2/day IV and cyclophosphamide 300 mg/m2/day IV for 3 days).
Diffuse Large B-Cell Lymphoma, High grade B-cell lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma (after two or more lines of therapy) 50 to 110 x 10^6 CAR-positive viable T cells as a single IV infusion, administered 2 to 7 days after lymphodepleting chemotherapy (fludarabine 30 mg/m2/day IV and cyclophosphamide 300 mg/m2/day IV for 3 days).
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Follicular, Mantle cell lymphoma, Marginal Zone B-Cell Lymphoma 90 to 110 x 10^6 CAR-positive viable T cells as a single IV infusion, administered 2 to 7 days after lymphodepleting chemotherapy (fludarabine 30 mg/m2/day IV and cyclophosphamide 300 mg/m2/day IV for 3 days).
Contraindications
- Known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol
—
Adverse Reactions
Most common (>=30%) Nausea, fatigue, vomiting, diarrhea, pyrexia
Serious Febrile neutropenia, pneumonia, acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, myelodysplastic syndrome
Postmarketing Pancytopenia, atrial fibrillation, congestive heart failure, myocardial infarction, anaphylaxis, progressive multifocal leukoencephalopathy, nephrogenic diabetes insipidus, pneumonitis, DRESS, non-melanoma skin cancer, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=30%) fever, CRS, fatigue, musculoskeletal pain, nausea
Serious CRS, encephalopathy, febrile neutropenia, sepsis, pneumonia, fever, hemorrhage, renal failure, aphasia, delirium, hemophagocytic lymphohistiocytosis
Postmarketing immune effector cell-associated neurotoxicity syndrome (ICANS), T cell malignancies, blindness
Pharmacology
Bendamustine is a bifunctional mechlorethamine derivative containing a benzimidazole ring that forms electrophilic alkyl groups, which create covalent interstrand DNA crosslinks leading to cell death via multiple pathways; it is active against both quiescent and dividing cells.
BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy; CAR binding to CD19 on tumor and normal B cells triggers CD3 zeta-mediated activation and cytotoxic killing of target cells, while 4-1BB (CD137) costimulatory signaling enhances CAR T cell expansion and persistence.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bendeka
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Breyanzi
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Bendeka
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Breyanzi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Bendeka
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Breyanzi
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bendeka.
Cost estimate not availableCancerCare: Chronic Lymphocytic Leukemia
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BendekaView full Bendeka profile
BreyanziView full Breyanzi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.